secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2023-11-30T23:59:59+00:00
Accession:  0001193125-23-285671
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec dosed first subject in Phase 1b/2a trial of BB-301 for OPMD dysphagia
-----------------------------------------------------------------------------

- BB-301 is a gene therapy candidate using Silence and Replace ddRNAi platform for Oculopharyngeal Muscular Dystrophy (OPMD).
- OPMD affects ~15,000 patients in US, Canada, Western Europe, and Israel; no approved therapies currently exist.
- Interim safety and efficacy data from the 52-week study expected in mid-2024.
- 19 subjects in the ongoing OPMD Natural History study are eligible to roll over into the BB-301 treatment study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523285671/0001193125-23-285671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523285671/d401028d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-285671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer